Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment (EAGLES)

Clinical Trial ID NCT03536780

Rank	Title	Journal	Year	PubWeight™‹?›
1	Cancer immunoediting: from immunosurveillance to tumor escape.	Nat Immunol	2002	14.75
2	Soft-tissue sarcomas in adults.	N Engl J Med	2005	5.97
3	The secret ally: immunostimulation by anticancer drugs.	Nat Rev Drug Discov	2012	3.60
4	Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.	J Clin Oncol	2002	3.49
5	Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).	Oncologist	2012	1.57
6	Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies.	Nat Rev Clin Oncol	2014	1.27
7	Chemoimmunotherapy: reengineering tumor immunity.	Cancer Immunol Immunother	2013	1.11
8	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).	Ann Oncol	2016	0.83
9	Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.	Lancet Oncol	2017	0.75
10	Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.	Lancet Oncol	2017	0.75